Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...
PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today ...
GC ranks as the fifth most common and fourth deadliest cancer worldwide, presenting significant health challenges, particularly in China where it is most prevalent and accounts for nearly half of ...
Drugging the Master Regulator TP53 in Cancer: Mission Possible? The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated ...
Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study. This is an ASCO Meeting ...
“The independent research groups, led by Prof. Scott W. Lowe and Christina Curtis,respectively, have uncovered a similar definitive pathway in the progression of gastric cancer (GC) initiated with ...
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...
An estimated 170,000 Australians were diagnosed with cancer in 2025. Many people know the causes of cancer are partly genetic. But how do your genes, which contribute so much of what makes you you, ...
Higgins is an advocate for people with Li-Fraumeni syndrome. I was born with an inherited cancer syndrome, Li-Fraumeni syndrome (LFS). A mutation on my Tp53 cancer suppressor gene makes me susceptible ...
* One sperm donor was linked to nearly 200 births across multiple countries * Several children inherited a high-risk TP53 cancer mutation * Case exposes gaps in genetic screening //and donor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results